SCHEMBL569909

SCHEMBL569909

Cn1ccnc1S(C)(=O)=O

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
LPO P22079 1/20 0.43
MCL1 Q07820 1/20 0.39
C1S P09871 1/20 0.38
HTT P42858 2/20 0.35
CHRM4 P08173 1/20 0.35
FDPS P14324 2/20 0.34
KDM4E B2RXH2 2/20 0.34
SMN1; SMN2 Q16637 2/20 0.33
MITF O75030 1/20 0.33
ALPL P05186 1/20 0.33
POLB P06746 1/20 0.33
MAPT P10636 1/20 0.33
APEX1 P27695 1/20 0.33
APOBEC3A P31941 1/20 0.33
APOBEC3G Q9HC16 1/20 0.33
PIK3C3 Q8NEB9 1/20 0.33
TSHR P16473 1/20 0.33
BRD4 O60885 1/20 0.33
HTR6 P50406 1/20 0.32
KAT5 Q92993 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL9033147 0.80 LPO (0.41) LPOMCL1C1SHTTCHRM4
SCHEMBL5610390 0.80 LPO (0.41) LPOMCL1C1SHTTCHRM4
SCHEMBL604082 0.80 LPO (0.41) LPOMCL1C1SHTTCHRM4
SCHEMBL5610393 0.80 LPO (0.41) LPOMCL1C1SHTTCHRM4
SCHEMBL20368151 0.78 HTT (0.41) LPOMCL1C1SHTTCHRM4
Hydrochloric Acid SCHEMBL28316626 0.78 LPO (0.40) LPOMCL1C1SHTTCHRM4
SCHEMBL26077977 0.77 LPO (0.43) LPOMCL1C1SHTTFDPS
SCHEMBL24051973 0.77 MCL1 (0.46) LPOMCL1C1SHTTCHRM4
SCHEMBL22951445 0.77 MCL1 (0.40) LPOMCL1C1SHTTCHRM4
SCHEMBL20364513 0.77 LPO (0.39) LPOMCL1C1SHTTCHRM4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 50 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12503457-B2 Fluorine-containing pyrimidine compound, and method for producing same UNIMATEC CO., LTD. (JP) 2025-12-23 US disclosed
EP-3405477-B1 INHIBITORS OF TRANSGLUTAMINASES ZEDIRA GMBH (DE) 2023-06-07 EP disclosed
US-20230117960-A1 FLUORINE-CONTAINING PYRIMIDINE COMPOUND, AND METHOD FOR PRODUCING SAME UNIMATEC CO., LTD. (JP) 2023-04-20 US disclosed
EP-4129993-A1 FLUORINE-CONTAINING PYRIMIDINE COMPOUND, AND METHOD FOR PRODUCING SAME Unimatec Co., Ltd. (JP) 2023-02-08 EP disclosed
US-20220186222-A1 LINKAGE MODIFIED OLIGOMERIC COMPOUNDS AND USES THEREOF IONIS PHARMACEUTICALS, INC. (US) 2022-06-16 US disclosed
WO-2021234459-A9 DOUBLE STRANDED OLIGONUCLEOTIDE COMPOSITIONS AND METHODS RELATING THERETO WAVE LIFE SCIENCES LTD. (SG) 2022-02-03 WO disclosed
WO-2021234459-A2 DOUBLE STRANDED OLIGONUCLEOTIDE COMPOSITIONS AND METHODS RELATING THERETO WAVE LIFE SCIENCES LTD. (SG) 2021-11-25 WO disclosed
US-11072634-B2 Inhibitors of transglutaminases ZEDIRA GMBH (DE) 2021-07-27 US disclosed
WO-2021030778-A1 LINKAGE MODIFIED OLIGOMERIC COMPOUNDS AND USES THEREOF IONIS PHARMACEUTICALS, INC. (US) 2021-02-18 WO disclosed
WO-2020108613-A1 HETEROAROMATIC DERIVATIVES FOR USE AS REGULATOR, PREPARATION METHOD THEREFOR AND USE THEREOF 江苏豪森药业集团有限公司 2020-06-04 WO disclosed
US-20080262042-A1 1-[5-(2-Fluoropyridin-3-yl)-1-(phenylsulfonyl)-1H-pyrrol-3-yl]-N-methylmethanamine or a salt thereof; acid secretion inhibitor; potassium-competitive acid blocker TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2008-10-23 US disclosed
US-20080262042-A1 1-[5-(2-Fluoropyridin-3-yl)-1-(phenylsulfonyl)-1H-pyrrol-3-yl]-N-methylmethanamine or a salt thereof; acid secretion inhibitor; potassium-competitive acid blocker TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2008-10-23 US disclosed
WO-2008108380-A2 PYRROLE COMPOUNDS TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2008-09-12 WO disclosed
EP-1944305-A1 Quinoline derivatives as phosphodiesterase inhibitors GLAXO GROUP LIMITED (GB) 2008-07-16 EP disclosed
US-20070142373-A1 Quinoline derivatives as phosphodiesterase inhibitors GLAXO GROUP LIMITED (GB) 2007-06-21 US disclosed
US-20070142373-A1 Quinoline derivatives as phosphodiesterase inhibitors GLAXO GROUP LIMITED (GB) 2007-06-21 US disclosed
US-20070049570-A1 Quinoline derivatives as phosphodiesterase inhibitors DEAN ANTHONY W 2007-03-01 US disclosed
US-20070049570-A1 Quinoline derivatives as phosphodiesterase inhibitors DEAN ANTHONY W 2007-03-01 US disclosed
WO-2004103998-A1 QUINOLINE DERIVATIVES AS PHOSPHODIESTERASE INHIBITORS GLAXO GROUP LIMITED (GB) 2004-12-02 WO disclosed
WO-2002074268-A2 DYEING COMPOSITIONS FOR THE DYEING OF KERATIN FIBRES, COMPRISING HETEROCYCLIC HYDRAZONE COMPOUNDS L'OREAL (FR) 2002-09-26 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-12503457-B2 Fluorine-containing pyrimidine compound, and method for producing same CNOT1, FXR1, CCNA1 LPO 4183/4885MCL1 1895/4885C1S 529/4885
US-20080262042-A1 1-[5-(2-Fluoropyridin-3-yl)-1-(phenylsulfonyl)-1H-pyrrol-3-yl]-N-methylmethanamine or a salt thereof; acid secretion inhibitor; potassium-competitive acid blocker REN, HRH2, ATP4A LPO 3323/4885MCL1 4384/4885C1S 916/4885
US-20230117960-A1 FLUORINE-CONTAINING PYRIMIDINE COMPOUND, AND METHOD FOR PRODUCING SAME CNOT1, FXR1, CCNA1 LPO 4183/4885MCL1 1895/4885C1S 529/4885
US-20070049570-A1 Quinoline derivatives as phosphodiesterase inhibitors PDE3B, PDE4B, PDE4A LPO 1165/4885MCL1 3338/4885C1S 1428/4885
US-11072634-B2 Inhibitors of transglutaminases TGM2, TGM3, TGM1 LPO 944/4885MCL1 4750/4885C1S 2025/4885
US-20070142373-A1 Quinoline derivatives as phosphodiesterase inhibitors PDE3B, PDE4B, PDE4A LPO 1165/4885MCL1 3338/4885C1S 1428/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.